Vertex got its start making a hepatitis C drug, but it has more recently homed in on medicine that treats symptoms of cystic fibrosis, a genetic disease that afflicts 75,000 people worldwide. Its two bestselling drugs, Orkambi and Kalydeco, account for 87% of its $2.6 billion in revenue. And in February, Vertex received approval of a third CF drug, Symdeko, which earned $186 million in its first quarter on the market—more than twice what analysts expected. The success of the drugs has helped Vertex more than double its revenue in three years.
Looking for leads, investment insights, or competitive intelligence?
News about Vertex Pharmaceuticals
With Congress split between Republicans and Democrats, pharma and biotech stocks are ready to surge.
From genetic testing giants to copycat drug manufacturers, here are the global companies set to make a mark on medicine.
Insights from our annual roundtable on the best stocks and the biggest risks.
Vertex stock is up more than 20%.
IBM dragged, serving as a tech stock outlier. Energy and health sectors advanced.